Clinical efficacy of tosufloxacin on the patients with urinary tract infections

単純性尿路感染症75症例, 複雑性尿路感染症63症例に対しTFLX (450 mg/day, 分3)を投与した.1)単純性では全例に起炎菌の消失をみ, 100%の臨床効果がえられたが, グラム陽性菌に菌交代したものが3例みられた.2)複雑性では起炎菌の消失は38例にみられ, 菌存続は16例に, 菌交代は9例にみられた.総合臨床効果は46例にみられたが, P. aeruginosa, S. marcescensを起炎菌とするものには効果が低かった.3)副作用はTFLX投与の161例につき検討し, 2例に腹部症状をみたが, いずれも軽微であり重篤なものはなかった.以上より尿路感染症症例に対するTFLX投与は安全でかつ有用な治療法であると思われたWe evaluated a newly developed quinolone agent, tosurofloxacin (TFLX), for its safety and clinical efficacy on patients with urinary tract infections (UTI). Among 138 cases satisfying the UTI criteria, 75 cases were acute simple UTI and 63 cases were chronic complicated UTI. In principle, a daily dose of 450 mg of TFLX was administered for 3 days and for 5 days for acute simple UTI and for chronic complicated UTI, respectively. Clinical efficacy of TFLX in these cases was evaluated according to the criteria of Japanese UTI committee. Bacteriologically, all 80 strains isolated from acute simple UTI were eradicated following TFLX administration. However, 2 gram positive strains and 1 gram negative strain, appeared following the treatment. In cases of chronic complicated UTI, 29 out of 32 gram positive strains and 29 out of 44 gram negative strains were eradicated. Among the isolated strains, P. aeruginosa and S. marcescens persisted, which suggests that they were less sensitive to TFLX. Overall clinical effectiveness rate of TFLX on acute simple UTI was 100%, while that on chronic complicated UTI was 73%. Adverse drug side effects were minimum, stomach discomfort and constipation was observed in one case each. These findings indicate that TFLX is a useful agent for the treatment of both simple and complicated UTI